EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Study 19 ( MCI186 ‐19) Post Hoc Analyses

Benjamin Rix Brooks iD, Jeremy Shefner, Stephen Apple iD

Muscle & Nerve · 2026

DOI: 10.1002/mus.70039 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Benjamin Rix Brooks und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Planning LLC, Charlotte, North Carolina, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Edaravone, Free Radical Scavengers. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Mitsubishi Tanabe Pharma America, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

While randomized controlled trials (RCTs) are the gold standard for evaluating the efficacy of therapies in amyotrophic lateral sclerosis (ALS), post hoc analyses can provide critical insights into clinical effectiveness, treatment durability, and subpopulation responses. Several post hoc analyses of Study MCI186‐19 (Study 19), the pivotal phase 3 RCT that supported the United States Food and Drug Administration approval of intravenous edaravone, have been performed to explore the broader clinical impact of this therapy. These analyses assessed the long‐term treatment efficacy, changes in individual ALS Functional Rating Scale–Revised item scores, survival and additional milestone events, and the impact of edaravone in patient subgroups defined by disease progression trajectories using latent class analysis. Collectively, these findings reinforce the long‐term clinical benefit of edaravone and demonstrate that edaravone may offer benefits across a spectrum of ALS disease trajectories, beyond those defined in the original study criteria. These studies help address questions not captured in the original RCT and may inform future trial design and treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisEdaravoneFree Radical ScavengersHumansTreatment OutcomeDisease ProgressionFemaleMale

Stichwörter der Autor:innen

ALSStudy 19amyotrophic lateral sclerosisclinicaledaravoneefficacypost hoc

Substanzen

EdaravoneFree Radical Scavengers

Autor:innen und Institutionen

  • Clinical Trials Planning LLC, Charlotte, North Carolina, USA.
  • Barrow Neurological Institute, Phoenix, Arizona, USA.
  • Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.

ORCID-Profile: Benjamin Rix Brooks, Stephen Apple

Förderung

  • Mitsubishi Tanabe Pharma America, Inc.

Zitieren

APA

Brooks, B. R., Shefner, J., & Apple, S. (2026). Study 19 ( MCI186 ‐19) Post Hoc Analyses. Muscle & Nerve. https://doi.org/10.1002/mus.70039

Vancouver

Brooks BR, Shefner J, Apple S. Study 19 ( MCI186 ‐19) Post Hoc Analyses. Muscle & Nerve. 2026. doi:10.1002/mus.70039

BibTeX
@article{Brooks2026,
  author = {Brooks, Benjamin Rix and Shefner, Jeremy and Apple, Stephen},
  title = {Study 19 ( MCI186 ‐19) Post Hoc Analyses},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70039}
}
Kostenlos starten →